1. Generics Bulletin
  2. >>Business

Lupin Strikes Deal For Anti-TB Drug Pretomanid

Company Plans To Commercialize Highly-Drug Resistant TB Medicine In 140 Countries

 
• By Akriti Seth

Lupin and non-profit organization TB Alliance have entered into a partnership for a new therapy for highly drug-resistant tuberculosis, pretomanid, to be distributed in 140 countries and territories.

TB tuberculosis lung 3D x-ray
Lupin has entered into a partnership for new Therapy for Highly Drug-Resistant TB • Source: Alamy

Lupin has announced acquiring rights to manufacture tuberculosis drug pretomanid from the non-profit drug developer TB Alliance. The deal gives Lupin “a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen,” the partners stated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business